Cargando…
P562: CAPILLARY BLOOD SAMPLING ALLOWS FEASIBLE METHOD FOR VENETOCLAX CONCENTRATION MEASUREMENT IN AN ACADEMIC MULTICENTER CLINICAL TRIAL CONTEXT
Autores principales: | Kytölä, Sari, Vänttinen, Ida, Kuusanmäki, Heikki, Ruokoranta, Tanja, Kurkela, Mika, Kiiski, Johanna, Holopainen, Annasofia, Partanen, Anu, Kuusisto, Milla E.L., Koskela, Sirpa, Räty, Riikka, Itälä-Remes, Maija, Ettala, Pia, Rimpiläinen, Johanna, Siitonen, Timo, Pyörälä, Marja, T. Backman, Janne, Niemi, Mikko, Kontro, Mika |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429111/ http://dx.doi.org/10.1097/01.HS9.0000969152.53119.c1 |
Ejemplares similares
-
Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia
por: Kuusanmäki, Heikki, et al.
Publicado: (2022) -
P409: BCL-2/BCL-XL INHIBITION INDUCES APOPTOSIS AND CIRCUMVENTS VENETOCLAX RESISTANCE IN TP53-MUTATED ACUTE MYELOID LEUKEMIA
por: Vänttinen, Ida, et al.
Publicado: (2023) -
P542: A PHASE I/II STUDY TO ASSESS SAFETY, TOLERABILITY AND PRELIMINARY EFFICACY OF BEXMARILIMAB IN COMBINATION WITH STANDARD OF CARE IN PATIENTS WITH MYELOID MALIGNANCIES (BEXMAB)
por: Kontro, Mika, et al.
Publicado: (2023) -
Hidden genomic MHC disparity between HLA-matched sibling pairs in hematopoietic stem cell transplantation
por: Koskela, Satu, et al.
Publicado: (2018) -
Immunomonitoring of MSC-Treated GvHD Patients Reveals Only Moderate Potential for Response Prediction but Indicates Treatment Safety
por: Keto, Joni, et al.
Publicado: (2018)